Implementation of Phase I clinical trial for ZHB110 sublingual tablet.

ZHB601 injection received clinical trial approval notice from the NMPA.

ZHB117 sublingual tablet received clinical trial approval notice from the NMPA.

ZHB114 for injection IND application approved by the FDA.

Implementation of phase I clinical trial for ZHB601 injection.

ZHB118 sublingual tablets received clinical trial approval notice from the NMPA.

ZHB111 injection receives the FDA approval for phase I clinical trial.

The new indication phase I clinical trial application for the anti-allergy desensitization drug ZHB110 sublingual tablets has been approved by the NMPA.

Implementation of phase I clinical trial application for anti-allergy desensitization drug ZHB117 sublingual tablets.

Implementation of phase I clinical trial application for anti-allergy desensitization drug ZHB118 sublingual tablets.

ZHB103 Injection IND application approved by the FDA.

ZHB103 Injection IND application for a new indication(TIA).

Obtained the aid of Jiangsu Province Excellence Postdoctoral Program.

IND application of ZHB103 Injection for a new indication (TIA) was approved by the FDA.

ZHB110 subligual tablet received Clinical Trial Approval Notice from the NMPA.

Implementation of Phase I Clinical Trial of ZHB103 Injection as a sponsor.

ZHB015 Injection received Clinical Trial Approval Notice from the NMPA.

Received the title of Talented Postdoctoral Research Station in Changzhou,China.

Passed the re-evaluation of National High-tech Enterprise.

As the applicant, carried out the phrase I clinical trial of ZHB107-108 Sublingual Tablets.

ZHB107-108 Sublingual Tablets for kids(Aging 3-17) obtained the clinical trial approval issued by NMPA.

ZHB114 for injection obtained the clinical trial approval issued by NMPA.

ZHB103 Injiction obtained the clinical trial approval issued by NMPA. 

8 invention patents were authorized in China.

Obtained the aid of Jiangsu Province Excellence Postdoctoral Program.

Obtained the seventy-forth batch general funding sponsored by the China Postdoctoral Science Foundation.

Received the title of Talented Postdoctoral Research Station in Changzhou,China.

Jiangsu Engineering Research Center for Precision Biomedicines.

Obtained IND Approval for ZHB107-108 Sublingual Tablet from the NMPA.

ZONHONBIO acquires 58% stake in GENHONBIO, resulting in a total ownership of 99%.

Gazelle Enterprise in Jiangsu Provincial High-Tech Industrial Development Zone.

ZHB114 Injection IND Clinical Trial Authorization (Greater China Region) and Technology Transfer.

Obtained 15 Granted Chinese Invention Patents and 2 Granted Invention Patents in the United States.

Jiangsu Provincial Excellent Postdoctoral Program Funding (Two Awards).

Excellent Post-doctoral Workstation of Changzhou City.

Obtained IND Approval for ZHB111 Injection from the NMPA.

ZHB111 Injection IND Clinical Trial Authorization (Greater China Region) and Technology Transfer.

Changzhou Engineering Research Center for Precision Biomedicines.

Fifth Edition of Changzhou Municipal Excellent Patent Award.

Obtained 12 Granted Chinese Invention Patents and 2 Granted Invention Patents in the United States.

Excellent Post-doctoral Workstation of Changzhou City.

Reevaluation of National High-Tech Enterprise.

Obtained IND Approval for ZHB206 Injection from the NMPA.

ZHB206 Injection IND Clinical Trial Authorization (Greater China Region) and Technology Transfer.

Obtained 22 Granted Chinese Invention Patents and 2 Granted Invention Patents in the United States.

The 68th Batch of China Postdoctoral Science Foundation General Funding.

Postdoctoral Research Funding in Jiangsu Province (Class C).

Excellent Post-doctoral Workstation of Changzhou City.

Obtained IND Approval for ZHB202 Injection from the NMPA.

ZHB202 Injection IND Clinical Trial Authorization (Greater China Region) and Technology Transfer.

Obtained 11 Granted Chinese Invention Patents and 1 Granted Invention Patents in the United States.

Jiangsu Provincial Funding for Postdoctoral Researchers.

Postdoctoral Research Funding in Jiangsu Province (Class A).

The 66th Batch of China Postdoctoral Science Foundation General Funding.

One of the Top Ten Postdoctoral Programme in Jiangsu Province.

Excellent Post-doctoral Workstation of Changzhou City.

Wholly-owned subsidiary GENSUNBIO underwent capital increase and equity expansion, with its main business adjusted to focus on biomedical materials and related products.

Obtained production licenses for 7 POCT products and started the products industrialization.

Obtained 4 Granted Chinese Invention Patents and 1 Granted Invention Patents in the United States.

Dual-Innovation Talents in Jiangsu Province (Dual-Innovation Doctor, Two Awards).

Postdoctoral Research Funding in Jiangsu Province (Class C).

Postdoctoral Research Funding in Jiangsu Province (Class B).

Excellent Post-doctoral Workstation of Changzhou City.

National High-Tech Enterprise.

Obtained 5 Granted Chinese Invention Patents.

Postdoctoral Research Funding in Jiangsu Province (Class C).

Excellent Post-doctoral Workstation of Changzhou City.

Gazelle Enterprise in National Independent Innovation Demonstration Zone in South Jiangsu.

Reevaluation of Private Techonology Enterprises in Jiangsu Province.

Obtained 11 Granted Chinese Invention Patents.

Science and Technology Service Backbone Enterprise in Jiangsu Province.

Excellent Postdoctoral Programme in Changzhou.

Postdoctoral Programme.

National Intellectual Property Standard Implementation Enterprise.

Advanced Intellectual Property Standard Implementation and Demonstration Enterprise in Jiangsu Province.

"Doctor Aggregation Plan Project" in Jiangsu Province.

Changzhou Municipal Science and Technology Plan (Science and Technology Support - Social Development) Project.

The participating subsidiary GENHON BIOTECH was established, specialized in the R&D, production and sales of in vitro diagnostic reagents and medical devices..

Obtained 9 Granted Chinese Invention Patents.

Intellectual Property Standard Implementation and Demonstration Enterprise in Jiangsu Province.

Jiangsu Research and Development Institution of Foreign Investment.

"Doctor Aggregation Plan Project" in Jiangsu Province.

Changzhou Municipal Science and Technology Plan (International Science and Technology Cooperation) Project.

Changzhou Municipal Science and Technology Plan (Applied Basic Research) Project.

Obtained 8 Granted Chinese Invention Patents.

"Doctor Aggregation Plan Project" in Jiangsu Province.

Technological Innovation Fund Project for Technology-based Enterprises in Jiangsu Province.

Science and technology SMEs in Jiangsu Province.

Changzhou Municipal Science and Technology Plan (Science and Technology Support - Social Development) Project.

Private Techonology Enterprises in Jiangsu Province.

Acquisition of the Wholly-owned GENSUN BIOMATERIALS CORPORATION.

2011.8.25 ZONHON BIOPHARMA INSTITUTE, INC. was founded.